Compare Equinor ASA (EQNR) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinor ASA vs Merck & Co., Inc. — how do they compare? Equinor ASA trades at $43.42 (market cap $101.62B), while Merck & Co., Inc. trades at $146.28 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 3.5× Equinor ASA's market cap, and Equinor ASA pays the higher dividend (3.63%). Which is the better fit depends on your goals — on Pluang, investors hold Equinor ASA for 59 Days and Merck & Co., Inc. for 98 Days on average.
| EQNR | MRK | |
|---|---|---|
Market Cap | $101.62B | $351.28B |
Volume | 4,991,782 | 7,969,665 |
Sector | Energy | Health |
52-Week High | $45.75 | $156.43 |
52-Week Low | $22.41 | $82.49 |
Typical Hold Time | 59 Days | 98 Days |
Enterprise Value | $110.31B | $398.04B |
Dividend Yield | 3.63% | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equinor (EQNR) trades at $43.415, up 4.34% with strong technical momentum and bullish moving average signals. The stock shows attractive valuation metrics with P/E of 11.63 and EV/EBITDA of 2.39, while maintaining solid profitability with 21.32% ROE. Recent earnings beat expectations in two of the last three quarters, and the company continues shareholder returns through dividends and buybacks.
EQNR presents compelling value with significant upside to the $87.50 consensus price target, though investors face risks from volatile energy prices and declining profit margins. The company's LNG expansion strategy and strong cash flow generation support long-term growth potential, while technical indicators suggest near-term bullish momentum may continue.
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
